Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6

Volz Y, Koschut D, Matzke-Ogi A, Dietz MS, Karathanasis C, Richert L, Wagner MG, Mely Y, Heilemann M, Niemann H, Orian-Rousseau V (2015)
Bioscience Reports 35(4): e00236.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Volz, Yvonne; Koschut, David; Matzke-Ogi, Alexandra; Dietz, Marina S.; Karathanasis, Christos; Richert, Ludovic; Wagner, Moritz G.; Mely, Yves; Heilemann, Mike; Niemann, HartmutUniBi ; Orian-Rousseau, Veronique
Abstract / Bemerkung
CD44v6, a member of the CD44 family of transmembrane glycoproteins is a co-receptor for two receptor tyrosine kinases (RTKs), Met and VEGFR-2 (vascular endothelial growth factor receptor 2). CD44v6 is not only required for the activation of these RTKs but also for signalling. In order to understand the role of CD44v6in Met and VEGFR-2 activation and signalling we tested whether CD44v6 binds to their ligands, HGF (hepatocyte growth factor) and VEGF (vascular endothelial growth factor), respectively. FACS analysis and cellular ELISA showed binding of HGF and VEGF only to cells expressing CD44v6. Direct binding of CD44v6 to HGF and VEGF was demonstrated in pull-down assays and the binding affinities were determined using MicroScale Thermophoresis, fluorescence correlation spectroscopy and fluorescence anisotropy. The binding affinity of CD44v6 to HGF is in the micromolar range in contrast with the high-affinity binding measured in the case of VEGF and CD44v6, which is in the nanomolar range. These data reveal a heparan sulfate-independent direct binding of CD44v6 to the ligands of Met and VEGFR-2 and suggest different roles of CD44v6 for these RTKs.
CD44s; CD44v6; HGF; Met; binding affinity; VEGF
Bioscience Reports
Page URI


Volz Y, Koschut D, Matzke-Ogi A, et al. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports. 2015;35(4): e00236.
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M. S., Karathanasis, C., Richert, L., Wagner, M. G., et al. (2015). Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports, 35(4), e00236. doi:10.1042/BSR20150093
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M. S., Karathanasis, C., Richert, L., Wagner, M. G., Mely, Y., Heilemann, M., Niemann, H., et al. (2015). Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports 35:e00236.
Volz, Y., et al., 2015. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports, 35(4): e00236.
Y. Volz, et al., “Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6”, Bioscience Reports, vol. 35, 2015, : e00236.
Volz, Y., Koschut, D., Matzke-Ogi, A., Dietz, M.S., Karathanasis, C., Richert, L., Wagner, M.G., Mely, Y., Heilemann, M., Niemann, H., Orian-Rousseau, V.: Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Bioscience Reports. 35, : e00236 (2015).
Volz, Yvonne, Koschut, David, Matzke-Ogi, Alexandra, Dietz, Marina S., Karathanasis, Christos, Richert, Ludovic, Wagner, Moritz G., Mely, Yves, Heilemann, Mike, Niemann, Hartmut, and Orian-Rousseau, Veronique. “Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6”. Bioscience Reports 35.4 (2015): e00236.

7 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer.
Zhu Y, Zhang H, Zhang G, Shi Y, Huang J., Ann Transl Med 7(5), 2019
PMID: 31019941
Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.
Morath I, Jung C, Lévêque R, Linfeng C, Toillon RA, Warth A, Orian-Rousseau V., Oncogene 37(11), 2018
PMID: 29321661
Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
Guo JY, Hsu HS, Tyan SW, Li FY, Shew JY, Lee WH, Chen JY., Oncogene 36(17), 2017
PMID: 27819672
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J., Oncoimmunology 6(12), 2017
PMID: 29209570
The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis.
Zhao L, Gu C, Huang K, Zhang Z, Ye M, Fan W, Han W, Meng Y., Arch Gynecol Obstet 294(5), 2016
PMID: 27300001
Expression and Function of CD44 in Epithelial Ovarian Carcinoma.
Sacks JD, Barbolina MV., Biomolecules 5(4), 2015
PMID: 26569327

41 References

Daten bereitgestellt von Europe PubMed Central.

Adhesion proteins meet receptors: a common theme?
Orian-Rousseau V, Ponta H., Adv. Cancer Res. 101(), 2008
PMID: 19055943
The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity.
Filla MS, Dam P, Rapraeger AC., J. Cell. Physiol. 174(3), 1998
PMID: 9462693
Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors.
Bonneh-Barkay D, Shlissel M, Berman B, Shaoul E, Admon A, Vlodavsky I, Carey DJ, Asundi VK, Reich-Slotky R, Ron D., J. Biol. Chem. 272(19), 1997
PMID: 9139688
Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation.
Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I., Cell 79(6), 1994
PMID: 7528103
Cell signaling by receptor tyrosine kinases.
Schlessinger J., Cell 103(2), 2000
PMID: 11057895
Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44.
Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A, Bennett KL., J. Biol. Chem. 274(4), 1999
PMID: 9891022
CD44, a therapeutic target for metastasising tumours.
Orian-Rousseau V., Eur. J. Cancer 46(7), 2010
PMID: 20303742
Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins.
Hasenauer S, Malinger D, Koschut D, Pace G, Matzke A, von Au A, Orian-Rousseau V., PLoS ONE 8(4), 2013
PMID: 23626807
A five-amino-acid peptide blocks Met- and Ron-dependent cell migration.
Matzke A, Herrlich P, Ponta H, Orian-Rousseau V., Cancer Res. 65(14), 2005
PMID: 16024611
A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.
Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, Orian-Rousseau V., Blood 114(25), 2009
PMID: 19773544
Neuropilins in physiological and pathological angiogenesis.
Staton CA, Kumar I, Reed MW, Brown NJ., J. Pathol. 212(3), 2007
PMID: 17503412
Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output.
Ballmer-Hofer K, Andersson AE, Ratcliffe LE, Berger P., Blood 118(3), 2011
PMID: 21586748
CD44 is required for two consecutive steps in HGF/c-Met signaling.
Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H., Genes Dev. 16(23), 2002
PMID: 12464636
Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F, Rabe DC, Bottaro DP., Expert Opin. Ther. Targets 16(6), 2012
PMID: 22530990
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.
Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P., Cell 65(1), 1991
PMID: 1707342
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.
Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, Bandyopadhyay A, Hartmann G, Butler PJ., Proc. Natl. Acad. Sci. U.S.A. 100(21), 2003
PMID: 14528000
Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB.
Niemann HH, Jager V, Butler PJ, van den Heuvel J, Schmidt S, Ferraris D, Gherardi E, Heinz DW., Cell 130(2), 2007
PMID: 17662939
Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells.
Dietz MS, Haße D, Ferraris DM, Gohler A, Niemann HH, Heilemann M., BMC Biophys 6(1), 2013
PMID: 23731667
InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase.
Shen Y, Naujokas M, Park M, Ireton K., Cell 103(3), 2000
PMID: 11081636
Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.
Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H., Mol. Biol. Cell 18(1), 2006
PMID: 17065554
Met, metastasis, motility and more.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF., Nat. Rev. Mol. Cell Biol. 4(12), 2003
PMID: 14685170
Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain.
Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M., J. Biol. Chem. 277(27), 2002
PMID: 11986311
Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis.
Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L., Dev. Cell 10(5), 2006
PMID: 16678777
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.
Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT., Genes Dev. 16(20), 2002
PMID: 12381667
Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA., Proc. Natl. Acad. Sci. U.S.A. 104(13), 2007
PMID: 17372204
Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.
Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C., EMBO J. 23(12), 2004
PMID: 15167892
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P., J. Clin. Invest. 114(10), 2004
PMID: 15545993
Integrin structures and conformational signaling.
Luo BH, Springer TA., Curr. Opin. Cell Biol. 18(5), 2006
PMID: 16904883
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment.
Xiong JP, Mahalingham B, Alonso JL, Borrelli LA, Rui X, Anand S, Hyman BT, Rysiok T, Muller-Pompalla D, Goodman SL, Arnaout MA., J. Cell Biol. 186(4), 2009
PMID: 19704023
The EGFR family: not so prototypical receptor tyrosine kinases.
Lemmon MA, Schlessinger J, Ferguson KM., Cold Spring Harb Perspect Biol 6(4), 2014
PMID: 24691965
Structural insights into Met receptor activation.
Niemann HH., Eur. J. Cell Biol. 90(11), 2011
PMID: 21242015
Structural basis of hepatocyte growth factor/scatter factor and MET signalling.
Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI., Proc. Natl. Acad. Sci. U.S.A. 103(11), 2006
PMID: 16537482


Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®


PMID: 26181364
PubMed | Europe PMC

Suchen in

Google Scholar